Helical Ltd. raises $10M in Seed

Helical Ltd., an emerging player in pharma artificial intelligence, has secured $10 million in seed funding led by Redalpine Venture Partners AG. The financing is aimed at enhancing the company’s AI-driven platform, which facilitates the transition from biological foundation models to reproducible, in-silico drug discovery workflows. Helical’s technology is tailored to integrate and streamline processes between drug discovery and machine learning applications within pharmaceuticals.

Established in 2024, Helical was conceived to address a critical gap in the deployment of biological foundation models—a type of advanced AI model trained on comprehensive datasets encompassing genomic and proteomic data. Such models possess the capability to predict biological system behaviors, yet they often falter when translating computational outputs into actionable, reproducible scientific decisions. Helical offers a solution through its virtual AI lab platform, merging an application layer that allows both scientists and engineers to work within a unified system.

The startup's platform comprises two main components: the Virtual Lab, which assists biologists and translational scientists, and The Model Factory, catering to machine learning engineers and data scientists. This integration is designed to bridge the divide between computational predictions and practical biological decision-making. Co-founder Rick Schneider emphasizes the necessity of a system that transforms these powerful models into actionable workflows scientists can utilize with confidence and precision.

The funding round also saw participation from Gradient, BoxGroup Ventures, Frst Capital, and individual investors such as Aidan Gomez, CEO of Cohere Inc.; Clement Delangue, CEO of Hugging Face; and Mario Goetze, a professional soccer player. According to Daniel Graf, a general partner at Redalpine, Helical is poised to capitalize on the convergence of biological foundation models and language reasoning tools, potentially revolutionizing how pharma AI is orchestrated from isolated models to a comprehensive virtual lab environment.

Helical is already operational with several leading pharmaceutical companies, including a public collaboration with Pfizer Inc. focusing on predictive safety biomarkers. The company asserts that its technology has significantly reduced discovery timelines from years to merely weeks in areas such as target identification and therapeutic design. Looking ahead, Helical aims to amplify its impact across the life sciences sector as it continues to develop its platform. The successful completion of this funding round positions Helical to scale its operations and further expand its market presence.